Incidence and Prognostic Significance of HER-2 Status Discordance Between Primary Breast Cancer and Paired Recurrent/Metastatic Lesions
NCT ID: NCT05510037
Last Updated: 2022-08-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1299 participants
OBSERVATIONAL
2021-01-01
2022-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Tumor Characteristics and Survival Rate of HER2-Low Breast Cancer Patients
NCT05754047
Dynamic Monitoring of HER2 and ctDNA Specific Mutations in Patients With Recurrent or Metastatic Breast Cancer by Digital PCR
NCT03947736
Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients
NCT07052734
MRD in High-risk EBC
NCT06566729
Discordant HER2/Neu Status of Breast Cancer.
NCT01935739
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HER2-0
no intervention
no intervention was needed
HER2-LOW
no intervention
no intervention was needed
HER2-POSITIVE
no intervention
no intervention was needed
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
no intervention
no intervention was needed
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fudan University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jian Zhang,MD
Director of the phase I clinical trial department
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jian Zhang, PHD
Role: PRINCIPAL_INVESTIGATOR
Fudan University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fudan University Shanghai Cancer Center
Shanghai, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
YBCSG-22-08
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.